Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pembrolizumab + bevacizumab + oxaliplatin + capecitabine
- Development stage
- Unknown
- Lead developer
- Merck
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
This is a combination therapy regimen consisting of pembrolizumab (an anti-PD-1 immune checkpoint inhibitor), bevacizumab (an anti-VEGF monoclonal antibody), oxaliplatin (a platinum-based chemotherapy agent), and capecitabine (an oral fluoropyrimidine chemotherapy). The combination is being investigated primarily for the treatment of metastatic colorectal cancer (mCRC), particularly in patients with proficient mismatch repair (pMMR) or microsatellite stable (MSS) tumors with high immune infiltrate. Clinical trials have shown promising response rates and disease control in these typically immunotherapy-resistant populations.
- Brand names
- KeytrudaAvastinXelodaEloxatin
- Other names
- XELOX + bevacizumab + pembrolizumabCAPOX + bevacizumab + pembrolizumab
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)DNAVEGFA (Vascular endothelial growth factor A)TS (Thymidylate synthase)
Beyond the preview
Go deeper on pembrolizumab + bevacizumab + oxaliplatin + capecitabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pembrolizumab + bevacizumab + oxaliplatin + capecitabine.